Strides Pharma Science
Strides Pharma Science Limited, commonly referred to as Strides, is a prominent player in the global pharmaceutical industry, headquartered in Bengaluru, India. Founded in 1990, the company has established a strong presence in various operational regions, including North America, Europe, and Africa. Strides focuses on the development, manufacturing, and marketing of a diverse range of pharmaceutical products, particularly in the areas of generic medications, complex generics, and over-the-counter (OTC) products. With a commitment to quality and innovation, Strides has achieved significant milestones, including the establishment of state-of-the-art manufacturing facilities and a robust pipeline of products. The company is recognised for its unique offerings in the injectable and oral dosage forms, positioning itself as a trusted partner in the healthcare sector. Strides Pharma Science continues to strengthen its market position through strategic collaborations and a dedication to meeting the evolving needs of patients worldwide.
DitchCarbon Score
How does Strides Pharma Science's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Strides Pharma Science's score of 4 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Strides Pharma Science's reported carbon emissions
In 2023, Strides Pharma Science reported total carbon emissions of approximately 24,448,000 kg CO2e, comprising about 4,490,000 kg CO2e from Scope 1 and about 19,548,000 kg CO2e from Scope 2. This reflects a reduction in Scope 1 emissions from about 6,206,000 kg CO2e in 2022, indicating a significant commitment to lowering direct emissions. However, Scope 2 emissions saw a slight decrease from approximately 19,960,000 kg CO2e in 2022. Looking ahead, Strides Pharma Science has not publicly disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. This suggests that while the company is actively monitoring and reducing its emissions, further commitments or structured reduction strategies may be necessary to align with industry standards for climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 6,206,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 19,960,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Strides Pharma Science is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
